IntelliCell BioScience Inc. Procedure Enables Norwegian Star Basketball Player to Fully Recover from Patella Tendinitis to Pl...
February 21 2012 - 9:02AM
Business Wire
IntelliCell BioScience, Inc. (OTCQB: SVFC) (PINKSHEETS: SVFC);
(“IntelliCell”) or the (“Company”), A full page Daily News article,
titled “Stem Sells” written by Sean Brennan published February 19,
2012,
http://www.nydailynews.com/sports/college/manhattan-basketball-torgrim-sommerfeldt-turned-stem-cell-treatment-back-court-article-1.1025227,
describes how Torgrim Summerfeldt’s budding basketball career was
saved through Dr. Anthony Maddalo’s treatment using IntelliCell
BioSciences proprietary SVF Cells (Stem Cell Therapy). Mr.
Summerfeldts, a former star player for the Norwegian National
Basketball Team, had undergone six knee surgeries and lived in
constant pain. He had forfeited his Wake Forest basketball
scholarship. Manhattan College took a chance on him and invited him
to join their team. Due solely to the two IntelliCell SVF (Stem
Cell) treatments in New York City by Dr. Maddalo near the end of
2010 and the beginning of 2011, he started his first game for
Manhattan College pain free on January 20, 2012.
Dr. Steven Victor, CEO of IntelliCell BioSciences, said “We are
very proud that our proprietary technology used by Dr. Maddalo was
able to rehabilitate Torgims’s knees and alleviate his pain. Sports
related injuries are a predominate focus for our Company. Doctors
using our proprietary technology have treated several professional
and college athletes with excellent results. Patients have seen
cartilage regrow in the knee. We are about to start a multi-center
study for several sports injury indications at major centers. We
are fortunate to have several top orthopedic surgeons on our
advisory board such as; Dr. Andrews, Dr. Hackel, Dr. Dugas and Dr.
Nicola. We believe the 2012–2013 years will see significant
revenues from the use of our technology to treat athletes. We
believe that this is a $1.3 billion market opportunity just in the
United States.
About IntelliCell BioSciences,
Inc.
IntelliCell is a pioneering regenerative medicine company
focused on the expanding regenerative medical markets using stromal
vascular fraction derived from adult adipose tissue. IntelliCell
intends to initially focus on selling laboratory suites and
licensing its technology to doctors for use in their offices for
their patients. The company is also setting up Centers of
Excellence where doctors can treat their patients. In addition,
IntelliCell BioScience in exploring storing the stromal vascular
fraction in cryostorage for future uses. The company is also
starting FDA IND clinical trials at major medical centers for
clinical indication approval. IntelliCell intends to pursue
expansion to secondary markets and beyond the U.S. through a
combination of company-owned and licensed clinical facilities. For
additional information, visit http://www.intellicellbiosciences.com
or call 212-249-3050.